In Her-2-negative breast cancers including TNBC breast cancer, high CLDN9 expression generally indicates a likelihood of patient resistance to chemotherapy, which may be reflected in the poor clinical outcome of the patients. The gene discussed is CLDN9; the disease is breast carcinoma.